8-K: Anteris Technologies Announces First Quarter 2025 Results and Provides Corporate Update

Anteris Technologies reported its Q1 2025 financial results, highlighted by the IDE submission for the PARADIGM Trial and the treatment of over 100 patients with DurAVR THV.

Summary

• Anteris Technologies Global Corp. announced its financial results for the quarter ended March 31, 2025.
• The company submitted an Investigational Device Exemption (IDE) to the FDA for the PARADIGM Trial, a global pivotal clinical trial for the DurAVR THV.
• Anteris achieved a clinical milestone of successfully treating over 100 patients with the DurAVR THV.
• One-year clinical data for DurAVR THV demonstrated sustained, favorable hemodynamic outcomes and a consistent safety profile.
• The company is expanding its global manufacturing capacity to support the PARADIGM Trial and anticipated commercial demand.
• Net sales for the quarter were $0.6 million, a decrease of $0.2 million compared to the same period in the prior year.
• Loss after income tax was $21.9 million, an increase of $5.8 million compared to the prior year.
• R&D expenses increased to $16.5 million due to upscaling manufacturing and preparing for the PARADIGM Trial.
• The company concluded the quarter with a cash position of $49.0 million.
• The PARADIGM Trial is expected to commence in the third quarter of 2025, pending FDA approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress on its clinical and regulatory milestones, but it is still operating at a loss. The successful completion of the PARADIGM Trial is critical for future success.

Positives

• The IDE submission for the PARADIGM Trial is a significant step towards regulatory approval.
• Reaching the milestone of 100 patients treated with DurAVR THV demonstrates growing physician confidence.
• Favorable one-year clinical data supports the safety and efficacy of the DurAVR THV.
• Expansion of manufacturing capacity prepares the company for the PARADIGM Trial and future commercialization.
• Inclusion in the FTSE Russell 2000 Index increases visibility to investors.
• The company has a solid cash position of $49.0 million.

Negatives

• Net sales decreased by $0.2 million (27%) compared to the same period in the prior year.
• The loss after income tax increased by $5.8 million (36%) compared to the prior year.
• The company is still operating at a significant loss.

Risks

• The PARADIGM Trial is pending FDA approval, and delays could impact the timeline.
• The company is reliant on the successful outcome of the PARADIGM Trial for regulatory approval.
• Supply chain risks are being mitigated by sourcing ADAPT tissue from both the U.S. and Australia.
• The company faces competition in the structural heart market.
• The company's future success depends on the successful commercialization of the DurAVR THV.

Future Outlook

The company anticipates commencing the PARADIGM Trial in the third quarter of 2025, pending FDA approval of the IDE. The company is also focused on scaling manufacturing capacity to meet the demands of the trial and anticipated commercial demand.

Management Comments

• Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris, stated that the company's focus has been on completing the technical, clinical, and regulatory work required to lodge the IDE application.
• He also highlighted the clinical milestone of over 100 patients treated with DurAVR and the scaling of the Clinical Team, Manufacturing, and Quality organizations.

Industry Context

Anteris is operating in the competitive structural heart market, focusing on aortic stenosis treatment. The DurAVR THV aims to differentiate itself through its biomimetic design and ADAPT tissue technology. The PARADIGM Trial's head-to-head comparison against commercially available devices (SAPIEN or Evolut series THV) will be crucial in establishing its competitive advantage.

Comparison to Industry Standards

• The DurAVR THV's one-year data showed favorable hemodynamics, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm2 and a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg.
• The company reported no prosthesis-patient mismatch (PPM) in small annuli patients, while current commercial devices have rates between 11.2% to 35.3% PPM, as indicated by the SMART Trial Investigators (Herrmann HC et al., 2024).
• The PARADIGM trial will compare the DurAVR THV against the Edwards Lifesciences SAPIEN and Medtronic Evolut series THVs.

Related Party Transactions

• During the first quarter of 2025, the aggregate amount of payments to related parties and their associates (which includes director fees, Company secretarial fees, CEO, President and CFO remuneration) was US$1.77 million.

Stakeholder Impact

• Shareholders: The progress of the PARADIGM Trial and potential commercialization of DurAVR THV could positively impact shareholder value.
• Patients: Successful development and approval of DurAVR THV could provide a new treatment option for aortic stenosis patients.
• Employees: Expansion of the company and manufacturing capacity could create new job opportunities.
• Clinical Sites: The PARADIGM Trial will involve clinical sites in the U.S., Canada, and Europe, providing opportunities for collaboration and research.

Next Steps

• Obtain FDA approval for the IDE submission for the PARADIGM Trial.
• Commence the PARADIGM Trial in the third quarter of 2025.
• Continue to scale up global manufacturing capacity.
• Continue to enroll patients in the DurAVR THV clinical program.
• Progress CE Mark approval in parallel to the PMA.

Key Dates

Keywords

DurAVR THV, PARADIGM Trial, aortic stenosis, transcatheter heart valve, clinical trial, FDA, Anteris Technologies, financial results